Risky Research Review Act

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. Issue: Avoid unnecessary restrictions on types of research including human embryonic stem cell, fetal tissue, gain of function, and animal research. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of National Institutes of Health (NIH)-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act. S.5295 - NIH Mentorship Modernization Act Issue: Provide feedback on National Institutes of Health (NIH) research training and mentors. Issue: Suggest opportunities to strengthen support for clinical trials. Issue: Educate Congress and the administration on challenges associated with slow pace of National Institutes of Health (NIH) obligations.

Client expense: $431,446 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office

Artificial Intelligence; Research security; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; H.R. 9102, the Biotech Investment National Security Act of 2026

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R.8845/S.TBD) - FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act, Title I and Title III, all provisions related to research and education in NASA, NSF, NIST, and NOAA. (H.R.9022/S.TBD) - FY2027 Appropriations for Energy and Water Development, Title III - all provisions related to science and research, including nuclear physics research facilities. Full funding for the CHIPS and Science Act of 2022 (P.L. 117-167) - which re-authorized and re-designated the research missions of the National Science Foundation (NSF); spur domestic innovation of advanced technologies through basic and applied research; authorized new R&D programs across federal research agencies; and for other purposes. Proposals to protect university IP, including under potential Bayh-Dole "march in" rights, and mitigate nefarious influence from hostile foreign actors. S.854/H.R.1864 - Risky Research Review Act - whole bill, potential impact on bio-medical research, regulatory burden, and efforts to increase oversight and accountability. Proposed regulatory changes to Facilities and Administration (F&A) cost agreements/negotiated indirect cost reimbursements for federally sponsored research, including the proposed FAIR Model for indirect cost reimbursements. EOs, grant rescissions/cancellations, regulatory changes, and policy shifts that affect faculty, researchers, students, programs, and core research and education missions.

Client expense: $90,000 · Firm income: Not reported

Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding, including the Department of Energy Genesis Mission Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue Proposed revisions to 2 CFR Part 200 (Uniform Guidance)

Client expense: $150,000 · Firm income: Not reported

Monitored and advised on Artificial Intelligence; Monitored S.854/H.R. 1864 - Risky Research Review Act; Monitored H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; Monitored and advised on H.R. 9102, the Biotech Investment National Security Act of 2026.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. Issue: Avoid unnecessary restrictions on types of research including human embryonic stem cell, fetal tissue, gain of function, and animal research. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.

Client expense: $821,438 · Firm income: Not reported

Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235); Cloud Labs to Advance Biotechnology Act of 2025 (S. 2676);

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235); Cloud Labs to Advance Biotechnology Act of 2025 (S. 2676);

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding, including the Department of Energy Genesis Mission Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue

Client expense: $190,000 · Firm income: Not reported

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.

Client expense: $577,720 · Firm income: Not reported

Monitored and advised on Artificial Intelligence; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue

Client expense: $150,000 · Firm income: Not reported

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.

Client expense: $708,395 · Firm income: Not reported

Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

NIH's proposed cap of 15% on F&A expenditures Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Ensure bill does not hamper the National Institutes of Health (NIH) peer review system. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research.

Client expense: $758,175 · Firm income: Not reported

Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1864 and S. 854: Risky Research Review Act A bill to amend title 31, United States Code, to establish the Life Sciences Research Security Board, and for other purposes (ALL). Presidential and executive actions to cap Facilities and Administrative (F&A) costs for research. Presidential and executive actions to freeze or terminate federal research grants. Presidential and executive actions to pause scientific research agency communications and meetings.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

NIH's proposed cap of 15% on F&A expenditures Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety

Client expense: $110,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). Issue: Provide input on proposed National Institutes of Health (NIH) optimization frameworks. H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support technical correction to ensure bill does not hamper the National Institutes of Health (NIH) peer review system.

Client expense: $831,429 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office

Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1864 and S. 854: Risky Research Review Act A bill to amend title 31, United States Code, to establish the Life Sciences Research Security Board, and for other purposes (ALL). Presidential and executive actions to cap Facilities and Administrative (F&A) costs for research. Presidential and executive actions to freeze or terminate federal research grants. Presidential and executive actions to pause scientific research agency communications and meetings.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

NIH's proposed cap of 15% on F&A expenditures Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA)

Client expense: $250,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE

Issues related to funding for university research opportunities via Fiscal Year 2025 and Fiscal Year 2026 Federal appropriations; Fiscal Year 2026 defense authorization bill; Issues related to Regional Biocontainment Laboratories (RBLs), cybersecurity, and military health; H.R. 1864 / S. 854 - Risky Research Review Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). Issue: Provide input on proposed National Institutes of Health (NIH) optimization frameworks. H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support technical correction to ensure bill does not paralyze National Institutes of Health (NIH) peer review system.

Client expense: $750,957 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office

Risky Research Review Act (H.R. 1864, S. 854); bioeconomy.

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Risky Research Review Act (S. 854/H.R. 1864) - all provisions Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence(INNOVATE) Act (S. 853) - provisions related to agency expenditures for SBIR programs

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE